Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, reported that the University of California, Los Angeles (UCLA) School of Medicine announced preliminary, positive topline data from the Phase II clinical trial evaluating Trimesta™ (oral estriol), the Company’s oral, once-daily treatment for relapsing-remitting multiple sclerosis (RRMS) in women. Synthetic Biologics Inc. (NYSEMKT:SYN) shares after opening at $1.90 moved to $2.10 on last trade day and at the end of the day closed at $1.45. Company price to sales ratio in past twelve months was calculated as – and price to cash ratio as 5.79. Synthetic Biologics Inc. (NYSEMKT:SYN) showed a negative weekly performance of -50.17%.
Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) a fully integrated specialty biopharmaceutical announced that certain members of the executive management team will participate in the Deutsche Bank Healthcare Conference to be held May 7-8 2014 at the InterContinental Hotel in Boston. Adrian Adams Chief Executive Officer and President is scheduled to present an overview of the Company and its product portfolio at 8:40 a.m. ET on Thursday May 8 2014. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) shares fell -17.73% in last trading session and ended the day on $22.51. AUXL return on equity ratio is recorded as -9.80% and its return on assets is -2.60%. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) yearly performance is 50.77%.
USANA Health Sciences (NASDAQ:USNA) announced its earnings results on Tuesday. The company reported $1.15 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.30 by $0.15, Analyst Ratings Network reports. The company had revenue of $182.40 million for the quarter, compared to the consensus estimate of $185.85 million. USANA Health Sciences, Inc. (NYSE:USNA) shares moved down -15.71% in last trading session and was closed at $67.86, while trading in range of $66.79 – $75.06. USANA Health Sciences, Inc. (NYSE:USNA) year to date (YTD) performance is -10.21%.
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of InspireMD, Inc. (NYSEMKT:NSPR). The investigation concerns possible violations of federal securities laws, and focuses on the Company’s operations and financial prospects. InspireMD Inc. (NYSEMKT:NSPR) weekly performance is -12.50%. On last trading day company shares ended up $2.10. InspireMD Inc. (NYSEMKT:NSPR) distance from 50-day simple moving average (SMA50) is -31.29%. Analysts mean target price for the company is $6.00.